MOSCOW, Feb. 13, 2013 — The Russian company Photonics, financed by Maxwell Biotech Venture Fund and RVC Seed Fund, sold its first stLase laser system to the global market, under the brand name Alta.
Photonics developed stLase with Dental Photonics Inc., which is commercializing the product and is planning to sell the systems in South Korea pending local regulatory approval. More than a dozen orders for laser systems have been placed in the US and Japan since early last year.
StLase is a compact laser system designed for soft-tissue treatments and procedures. The system consists of a main console, equipped with a 7-in. interactive touch screen and the applicable modules, which can be attached to the console’s side. The device can be used in cardiovascular, obstetric, ENT, proctology and gynecology surgeries as well as other medical fields.
“Photonics’ recent sales are very important news for our fund,” said Dr. Dmitry Popov of Maxwell Biotech Venture Fund. “StLase has become the first world-class innovative product developed with the participation of Maxwell Biotech Venture Fund to enter both global and the Russian markets and is already being used to treat patients in the US, Russia and Japan."
"Photonics is a unique illustration of the global competitiveness of Russian technologies, developed in partnership with international experts,” said Alexey Teleshev, CEO of RVC Seed Fund. “At the moment, the project has reached a major milestone and has started generating revenue as a result of the first sales in Russia and abroad."
For more information, visit: www.maxwellbiotech.com